Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells
- 21 July 2021
- journal article
- review article
- Published by Springer Nature in Molecular Diagnosis & Therapy
- Vol. 25 (5) , 549-562
Abstract
Metastasis is the main cause of cancer death. Metastatic foci are derived from tumor cells that detach from the primary tumor and then enter the circulation. Circulating tumor cells (CTCs) are generally associated with a high probability of distant metastasis and a negative prognosis. Most CTCs die in the bloodstream, and only a few cells form metastases. Such metastatic CTCs have a stem-like and hybrid epithelial-mesenchymal phenotype, can avoid immune surveillance, and show increased therapy resistance. Targeting metastatic CTCs and their progenitors in primary tumors and their descendants, particularly disseminated tumor cells, represents an attractive strategy for metastasis prevention. However, current therapeutic strategies mainly target the primary tumor and only indirectly affect metastasis-initiating cells. Here, we consider potential methods for preventing metastasis based on targeting molecular and cellular features of metastatic CTCs, including CTC clusters. Also, we emphasize current knowledge gaps in CTC biology that should be addressed to develop highly effective therapeutics and strategies for metastasis suppression.Keywords
Funding Information
- Russian Science Foundation (19-75-3001)
This publication has 162 references indexed in Scilit:
- Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes MetastasisCancer Cell, 2011
- Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patientsGynecologic Oncology, 2011
- Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapyInternational Journal of Cancer, 2011
- PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical modelsBritish Journal of Cancer, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lungBritish Journal of Cancer, 2009
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in miceJournal of Cellular Biochemistry, 2008
- Multistep Nature of Metastatic InefficiencyThe American Journal of Pathology, 1998